Manulife (Manufacturers Life Insurance)
SLNO

Manulife (Manufacturers Life Insurance)’s Soleno Therapeutics SLNO Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,878
Closed -$766K – 2974
2026
Q1 		$766K Sell
22,878
-18,308
-44% -$718K ﹤0.01% 1968
2025
Q4 		$1.91M Sell
41,186
-42,506
-51% -$2.33M ﹤0.01% 1542
2025
Q3 		$5.66M Buy
83,692
+6,429
+8% +$477K ﹤0.01% 1122
2025
Q2 		$6.47M Buy
77,263
+24,222
+46% +$1.81M 0.01% 1050
2025
Q1 		$3.79M Buy
53,041
+1,884
+4% +$91.7K ﹤0.01% 1279
2024
Q4 		$2.3M Sell
51,157
-1,477
-3% -$76.5K ﹤0.01% 1500
2024
Q3 		$2.66M Buy
52,634
+3,226
+7% +$154K ﹤0.01% 1451
2024
Q2 		$2.02M Buy
49,408
+27,020
+121% +$1.15M ﹤0.01% 1495
2024
Q1 		$958K Buy
+22,388
New +$1.01M ﹤0.01% 1883
2021
Q1 		– Sell
-1,218
Closed -$35K – 3120
2020
Q4 		$35K Sell
1,218
-1,088
-47% -$31.4K ﹤0.01% 2978
2020
Q3 		$87K Buy
+2,306
New +$67.4K ﹤0.01% 2824

Manulife (Manufacturers Life Insurance)'s SLNO Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 22,878 shares — an estimated $766K sold.

Manulife (Manufacturers Life Insurance) first reported a position in SLNO in Q3 2020 and held it in 11 quarters. The position peaked at $6.47M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • Manulife (Manufacturers Life Insurance) reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Manulife (Manufacturers Life Insurance) sold 22,878 Soleno Therapeutics shares in Q2 2026, an estimated $766K.
  • Manulife (Manufacturers Life Insurance) first reported a position in Soleno Therapeutics in Q3 2020 and held it in 11 quarters.
  • Manulife (Manufacturers Life Insurance)'s Soleno Therapeutics position peaked at $6.47M in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.